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Abstract
Background: The vast majority of cases with Beckwith-Wiedemann syndrome (BWS) are caused by a molecular
defect in the imprinted chromosome region 11p15.5. The underlying mechanisms include epimutations,
uniparental disomy, copy number variations, and structural rearrangements. In addition, maternal loss-of-function
mutations in CDKN1C are found. Despite growing knowledge on BWS pathogenesis, up to 20% of patients with
BWS phenotype remain without molecular diagnosis.
Case presentation: Herein, we report an Iranian family with two females affected with BWS in different generations.
Bisulfite pyrosequencing revealed hypermethylation of the H19/IGF2: intergenic differentially methylated region (IG
DMR), also known as imprinting center 1 (IC1) and hypomethylation of the KCNQ1OT1: transcriptional start site (TSS)
DMR (IC2). Array CGH demonstrated an 8 Mb duplication on chromosome 11p15.5p15.4 (205,827-8,150,933) and a 1
Mb deletion on chromosome 9p24.3 (209,020-1,288,114). Chromosome painting revealed that this duplication-
deficiency in both patients is due to unbalanced segregation of a paternal reciprocal t(9;11)(p24.3;p15.4) translocation.
Conclusions: This is the first report of a paternally inherited unbalanced translocation between the chromosome 9 and
11 short arms underlying familial BWS. Copy number variations involving the 11p15.5 region are detected by the
consensus diagnostic algorithm. However, in complex cases which do not only affect the BWS region itself,
characterization of submicroscopic chromosome rearrangements can assist to estimate the recurrence risk and possible
phenotypic outcomes.
Keywords: Familial Beckwith-Wiedemann syndrome, Copy number variation, Duplication-deficiency, Genomic
imprinting, Submicroscopic chromosome rearrangement, Reciprocal translocation
Background
Beckwith-Wiedemann syndrome (BWS; MIM #130650) is
a clinically variable overgrowth syndrome with a preva-
lence of 1:10,340 live-births [1, 2]. Cardinal features of the
consensus Beckwith-Wiedemann spectrum (BWSp) scor-
ing system [3] include macroglossia, exomphalos, latera-
lized overgrowth, hyperinsulinism, and predisposition to
embryonal tumors (e.g. multifocal and/or bilateral Wilms
tumor or nephroblastomatosis). The BWS locus on
chromosome 11p15.5 contains several genes involved in
cell proliferation, which are regulated by two differentially
methylated regions (DMRs), which function as imprinting
centers (ICs). The paternally methylated H19/IGF2:IG
DMR (IC1) controls paternal expression of the insulin-like
growth factor 2 (IGF2), which is implicated in growth and
tumorigenesis, and maternal expression of H19, a non-
coding RNA, which restricts growth by way of a cis con-
trol on IGF2 and may also have a tumor suppressor func-
tion. The maternally methylated KCNQ1OT1:TSS DMR
(IC2) controls paternal expression of the long non-coding
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RNA KCNQ1OT1, which in turn silences KCNQ1 and
presumably also CDKN1C in cis via chromatin remodel-
ing. The cyclin-dependent kinase inhibitor 1C (CDKN1C)
is a negative regulator of cell proliferation [4–9].
There is a complex interplay of paternally expressed
growth-promoting (IGF2 and KCNQ1OT1) and mater-
nally expressed growth-inhibiting factors (H19 and
CDKN1C) in the BWS region. BWS can arise through
various molecular mechanisms. Aberrant hypomethyla-
tion of IC2 accounts for approximately 50%, segmental
paternal uniparental disomy (UPD) for ~ 20%, loss-of-
function mutations of the maternal CDKN1C gene for
5–10%, and hypermethylation of IC1 for ~ 5% of pa-
tients. The majority (80–85%) of BWS cases occur spor-
adically [3, 8, 9]. Familial forms (15–20%) may be caused
by maternal loss-of-function CDKN1C mutations, bal-
anced chromosomal rearrangements involving the ma-
ternal chromosome 11p15.5, maternal deletions and
OCT4/SOX2 binding site mutations within IC1, or copy
number variations (CNVs) of the paternal allele [8–11].
Because of its broad phenotypic spectrum and overlap
with other overgrowth syndromes, the clinical diagnosis
of BWS is challenging. Best practice guidelines have
been developed for a standardized clinical and molecular
diagnostics and management of patients with Beckwith-
Wiedemann spectrum [3]. Here, we describe an Iranian
family with BWS-affected individuals in two generations
due to a familial reciprocal translocation t(9;11)(p24.3;
p15.4).
Case report
An Iranian family presented with two females (aunt and
niece) affected with BWS in different generations (Fig. 1).
The aunt II.7 was born to a healthy couple as the last of
five children. The pregnancy was unremarkable, except
for accelerated intrauterine growth. Sporadic seizures dur-
ing childhood were medicated and since then she has been
seizure-free. Because of severe anemia she was treated
with folic acid. Now at age 36, she exhibits a round face
with full cheeks, macroglossia, and intellectual disability
(ID). The niece III.1 is the first child of the oldest brother
of female II.7 with BWS. She (III.1) was delivered at 35
weeks of gestation with a birth length of 47 cm (Z score 1)
and a birth weight of 3150 g (Z score 2). Apart from oligo-
hydramnion, no pregnancy-related medical problems were
observed. At birth she showed microcephaly, a round face
with full cheeks, a broad nasal bridge, and macroglossia.
Starting from the age of 15months, she exhibited recur-
ring seizures and upper respiratory tract infections. Now
at an age of two years, she displays global developmental
delay and agitation.
Bisulfite pyrosequencing
Genomic DNA was extracted from whole blood following
the standard salt extraction method and bisulfite con-
verted with the EpiTect Fast Bisulfite Conversion Kit
(Qiagen, Hilden, Germany). PCR and sequencing primers
(Table 1) were adopted from Paganini et al., 2015 [12].
Amplification was performed with an initial denaturation
step at 95 °C for 5min, 40 cycles of 95 °C for 30 s, primer-
specific annealing temperature (54 °C for IC1 and 57 °C
for IC2) for 30 s, 72 °C for 45 s, and a final extension step
at 72 °C for 5min. Bisulfite pyrosequencing was per-
formed on a PyroMark Q96 MD Pyrosequencing System
using the PyroMark Gold Q96 CDT Reagent Kit (Qiagen)
and 0.5 μl of sequencing primers (10 μM). Data analysis
was done with the Pyro Q-CpG software (Qiagen).
Fig. 1 The upper part shows the pedigree of a three-generation Iranian family with two females affected with BWS (black circles). Balanced
translocation carriers are represented by a dot in the middle of the symbol. The photographs below show the two-year old girl III.1 and
the 36-year-old woman II.7, exhibiting macroglossia and typical facial appearance of BWS
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The mean methylation β values (duplicate measure-
ments of 4 CpGs each for IC1 and IC2) were compared
between the two study samples, one BWS sample with
upd(11p15.5)pat, and 7 normal controls. We found
hypermethylation of IC1 and hypomethylation of IC2 in
both affected individuals II.7 (IC1 56.8%, IC2 29.8%) and
III.1 (IC1 53.5%, IC2 32.6%), compared to normal con-
trols (mean IC1 38.5%, IC2 45.4%). The gain of methyla-
tion by ≥ 15 percentage points (compared to the mean
of controls) at IC1 is consistent with the presence of two
methylated paternal and one unmethylated maternal al-
lele(s), whereas the loss of methylation by > 12 percent-
age points at IC2 is due to two unmethylated paternal
and one methylated maternal allele(s). Methylation (IC1
50.5%, IC2 35.8%) of the upd(11p15.5)pat sample is con-
sistent with a mosaic UPD with a large proportion of
normal cells. For a non-mosaic upd(11p15.5)pat span-
ning both domains one would expect IC1 methylation
levels > 80% and IC2 methylation levels < 20% by bisul-
fite pyrosequencing. The box plots in Fig. 2 demonstrate
the range of methylation variation in normal individuals.
At IC1 (median 38.8%, IQR 3.0%) the methylation mea-
surements of the three BWS patients are more than
three interquartile ranges (IQRs) away from the box,
whereas at IC2 (median 44.0%, IQR 7.2%) the distance is
between one and two IQRs. However, the larger normal
Table 1 PCR and sequencing primersa for bisulfite pyrosequencing















aAdopted from Paganini et al., 2015 [12]
bGenomic coordinates are based on Ensembl release 75
cPrimer is biotinylated at the 5′ end
Fig. 2 Mean methylation values of IC1 and IC2, measured by bisulfite pyrosequencing, in one BWS sample with mosaic upd(11p15.5)pat,
indicated by a green diamond, and the two affected family members II.7 and III.1, indicated by orange and red symbols. The black box plots
demonstrate methylation variation among 7 control samples without BWS. The bottom of the box indicates the 25th percentile, the top the 75th
percentile. The median is represented by a horizontal line and the mean by an open diamond symbol within the box. Whiskers represent the
observed methylation range in normal samples
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variation at IC2 is mainly due to samples in the third
and fourth quartiles. The analyzed BWS samples are
clearly hypomethylated at IC2. Between-group compari-
sons revealed a significant difference (T test; p < 0.0001
for IC1 and p = 0.003 for IC2) between BWS samples
and healthy controls.
Molecular cytogenetic analyses
Array comparative genomic hybridization (CGH) was
performed using the CGX DNA labeling kit (PerkinEl-
mer, Rodgau, Germany) and the CGX-HD array chip
(PerkinElmer) that covers clinically relevant regions with
180,000 oligonucleotide markers. A female genomic
DNA sample served as a reference. The hybridized chip
was scanned with the NimbleGen MS-200 Microarray
Scanner (Roche Diagnostics, Mannheim, Germany).
Data analysis was conducted with CytoGenomics 2.5
(Agilent, Waldbronn, Germany) and Genoglyphix 3.0
(PerkinElmer) software using annotations from human
genome assembly GRCh37. Chromosomal microarray
analysis revealed a 7.95Mb heterozygous copy number
gain including the entire BWS-critical region on
chromosome 11p15.5p15.4 (arr[hg19] 11p15.5p15.4(205,
827-8,150,933) × 3), along with a 1.08Mb heterozygous
copy number loss of chromosome 9p24.3 (arr[hg19]
9p24.3(209,020-1,288,114) × 1) in affected individuals
II.7 and III.1 (Fig. 3, left side).
Chromosomes were prepared from lymphocyte cell cul-
tures according to standard protocols. Fluorescence in situ
hybridization (FISH) was performed with XCyting
Chromosome Paints (MetaSystems, Altlussheim, Germany)
for chromosomes 9 and 11. Hybridized chromosome slides
were analysed using an epifluorescence microscope Axio
imager A1 (Carl Zeiss, Jena, Germany), equipped with a
FISHView system (Applied Spectral Imaging, Edingen-
Neckarhausen, Germany). At least ten metaphases of each
proband were evaluated. FISH analysis with chromosome 9
(red) and 11 (green) painting probes revealed a derivative
chromosome 9 with chromosome 11 material on the short-
arm subtelomere in both affected females (II.7 and III.1)
(Fig. 3, right side). The father (I.2) of the aunt (II.7) and the
father (II.2) of the niece (III.1) showed a reciprocal ex-
change of material between chromosomes 9 and 11, con-
sistent with a reciprocal t(9;11)(p24.3;p15.4) translocation
(Fig. 3, right). The mothers (I.1 and II.1) of both affected fe-
males showed normal FISH karyotypes.
Discussion and conclusion
The main cause (~ 40%) of familial BWS are maternal
loss-of-function mutations in CDKN1C. The remaining
cases are due to maternally inherited balanced transloca-
tions and inversions with breakpoints in chromosome
11p15.5 or to paternally derived 11p15.5 duplications,
which may be the unbalanced segregation products of
familial balanced translocations [3, 8, 9]. It has been
Fig. 3 The left side shows the results of array CGH analysis of females II.7 and III.1, affected with BWS. The hybridization profiles are consistent
with a heterozygous loss of chromosome 9p24.3, (209,020-1,288,114) × 1, and a heterozygous gain of chromosome 11p15.5p15.4, (205,827-
8,150,933) × 3. The right side shows representative metaphase spreads of the affected females and their fathers, hybridized with chromosome 9
(red) and chromosome 11 (green) painting probes. II.7 and III.1 display a derivative chromosome 9 with chromosome 11 material on the short
arm. The fathers I.2 and II.2 are endowed with a reciprocal translocation between chromosomes 9p and 11p
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hypothesized [13] that maternal balanced rearrange-
ments interfere with epigenetic resetting of the BWS-
critical region in the female germline by a cis-acting ele-
ment(s). This view is supported by several publications,
describing individuals with BWS and balanced maternal
t(11;17)(p15.5;q21.3) and t(9;11)(p11.2;p15.5) transloca-
tions [14, 15]. A number of paternal reciprocal translo-
cations associated with 11p15.5 duplications in the
affected children have been reported [13, 16–18]. Recur-
ring translocations, in particular between 5p and 11p
may be driven by sequence homologies. In a large study
using methylation-specific multiplex ligation-dependent
probe amplification [8], 14 (8%) of 167 patients with the
molecular diagnosis of BWS exhibited CNVs in the
11p15.5 region. One of 6 duplication patients exhibited
a paternally inherited unbalanced t(4;11) translocation.
Consistent with best practice guidelines [3, 9], the
BWS diagnosis in the two affected females of our family
was first confirmed by methylation testing. Bisulfite py-
rosequencing is a relatively simple but highly accurate
method for quantitative methylation measurements. In
our experience, the methylation difference between tech-
nical replicates (including bisulfite conversion) is in the
order of 1–2 percentage points. Since pyrosequencing
provides the mean methylation of a large number of
DNA molecules in a genomic DNA sample, it does not
distinguish between paternal and maternal allele methy-
lation of imprinted alleles. Theoretically, one would ex-
pect 50% methylation of imprinted genes with one
methylated and one unmethylated allele. However, the
measured methylation values do not only depend on the
methylation status of a given CpG(s) but also on assay
design (that can lead to biased amplification of either
the unmethylated or the methylated allele), genetic
variation, and parental factors [19]. Nevertheless, the
measured methylation levels indicated clear hypermethy-
lation of IC1 and hypomethylation of IC2 in both affected
females and a mosaic upd(11p15.5)pat, compared to nor-
mal controls. The described assay is inexpensive, fast and
can be easily adopted in molecular genetic laboratories,
however before application in routine diagnostics it needs
to be validated on a larger number of BWS and control
samples. Based on our preliminary analysis of 3 BWS and
7 control samples we suggest that hypermethylation or hy-
pomethylation by ≥ 10 percentage points is indicative of
abnormal methylation patterns. Methylation variation at
IC1 among normal individuals appears to be smaller
than that at IC2 and, consequently, the sensitivity of
the assay may be better for IC1. It is interesting to
note that methylation at both IC1 and IC2 differs by
approximately 3 percentage points between the niece
and aunt carrying the same unbalanced translocation.
This is likely due to confounding factors such as age
and BMI [19–21].
The combination of 11p15.5p15.4 duplication and
9p24.3 deletion, detected by array CGH in our patients
was consistent with an unbalanced meiotic segregation
of a balanced paternal translocation. Indeed a reciprocal
t(9p;11p) translocation was demonstrated by chromo-
some painting in the unaffected fathers I.2 and II.2. Male
balanced translocation carriers (I.2 and II.2) have a re-
currence risk up to 25% for a child with BWS due to a
11p15.5p15.4 duplication and 9p24.3 deficiency. The re-
ciprocal condition of a 11p15.5p15.4 deletion involving
131 OMIM genes and 9p24.3 duplication may cause
pregnancy loss (as observed in the possible translocation
carrier II.5) or a child with syndromal ID and a phenotype
more severe than BWS (see https://decipher.sanger.ac.uk).
Chromosome analysis of the healthy sisters (II.3. II.4, and
II.5) of the affected aunt (II.7) was recommended.
It has been reported [6, 17, 18, 22] that patients with
BWS due to a paternally inherited 11p15.5 duplication
exhibit macroglossia, distinct craniofacial features, in-
cluding prominent occiput and forehead, a round face
with full cheeks, broad and flat nasal bridge, micro-
gnathia, hypertelorism, deep set eyes with epicanthus as
well as an increased risk for ID. Although our two pa-
tients fit well to this description, the considerable size
variation of the duplicated 11p15.5 segments and add-
itional chromosomal imbalances in some patients render
such genotype-phenotype correlations difficult. We can-
not exclude that part of the symptoms in our patients
are caused or modulated by heterozygous loss of 9p ma-
terial, including the OMIM genes DOCK8, KANK1,
DMRT1, DMRT2, and DMRT3, or the gain of 11p ma-
terial, involving 131 OMIM genes, including the entire
beta globin locus. A duplication of the Hbb (epsilon-,
gamma-G-, gamma-A-, delta-, and beta-globin) gene
cluster has been reported in a women with sickle cell-
like anemia [23] and could also contribute to the severe
anemia in the aunt with BWS. Homozygous or com-
pound heterozygous mutations in the dedicator of cyto-
kinesis 8 (DOCK8) gene cause hyper-IgE syndrome [24].
It is possible that DOCK1 haploinsufficiency contributes
to recurrent bacterial infections in one of our patients.
Paternal deletions of the KN motif and ankyrin repeat
domains 1 (KANK1) gene have been associated with
cerebral palsy spastic quadriplegic type 2 (CPSQ2), a se-
vere central nervous development disorder [25]. The
imprinted-like behaviour of paternal KANK1 deletions
was explained by hypomethylation of the neighboring
DMRT1 gene, leading to expression of an antisense tran-
script, which represses KANK1 in trans. Since the
DMRT genes in cis are deleted in our patients, they do
not present with CPSQ2. Both gains and losses of
KANK1 have been associated with childhood seizures
and developmental delay [26] which are seen in our two
patients but are not typical for BWS. Haploinsufficiency
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of doublesex- and mab3-related transcription factors
(DMRT) in 9p24.3 has been associated with failure of
testicular development and XY sex reversal [27, 28]. Fe-
males display a wide phenotypic spectrum ranging from
primary ovarian failure to mild gonadotropin hyperrespon-
siveness, normal genitalia and pubertal development [29, 30].
Our patients showed normal sexual development by age.
The classical monosomy 9p syndrome (MIM #158170),
which is characterized by trigonocephaly, midface hypo-
plasia, long philtrum, hypotonia and ID results from
chromosome 9p22p23 deletions [31]. Thus, the critical re-
gion lies proximal of the 9p24.3 segment which is deleted
in our patients. Overall, reciprocal translocations between
the chromosome 9 and 11 short arms appear to be very
rare. A balanced t(9;11)(p11.2;p15.5) translocation in a girl
with BWS was inherited from her phenotypically normal
mother, who was a de novo translocation carrier [15]. A
balanced t(9;11)(p21.2;p14.2) translocation not affecting
the BWS-critical region was reported in a neonate with
epicanthal folds, flat nasal bridge, small mouth, micro-
gnathia, low-set ears, and cleft palate [32]. Her phenotype,
which does not include features of BWSp, may be caused
by a disrupted gene(s) and/or microdeletions in the break-
point regions.
In the BWS family described here the results of methy-
lation analysis were consistent with a paternal 11p15.5 du-
plication. Array CGH revealed that BWS in the two affect
females was due to an unbalanced segregation of a pater-
nal reciprocal t(9;11)(p24.3;p15.4) translocation. BWS can
be caused by both balanced and unbalanced 11p15.5
translocations originating from either parent. Unbalanced
translocations will be detected by assessing CNVs in the
11p15.5 region, which is part of the recommended diag-
nostic algorithm for BWS [3]. Conventional chromosome
analyses are usually performed in familial cases of BWS,
especially those without CDKN1Cmutations. Since the re-
currence risk of BWS and possible phenotypic outcomes
depend on size, gene content, copy number, and parental
inheritance of the involved chromosome regions, it is rea-
sonable to characterize the underlying submicroscopic
chromosome rearrangements in translocation carriers and
their families.
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